Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Development of a New Algorithm to Determine the Activity of Disease: Deep Endoscopic Remission Assessed by a Surrogate Biomarker in Patients With IBD.

NCT01861288 is registered in ClinicalTrials.gov with Herlev Hospital as lead sponsor.

NCT NCT01861288
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01861288 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Development of a New Algorithm to Determine the Activity of Disease: Deep Endoscopic Remission Assessed by a Surrogate Biomarker in Patients With IBD.
Lead sponsor
Herlev Hospital
Phase
Observational
Overall status
Completed
Start date
November 1, 2013
Completion date
February 28, 2018
Enrollment
157 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease, inflammatory bowel disease, ulcerative colitis